Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-alpha2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study

Trial Profile

Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-alpha2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 14 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2018.
    • 07 Jun 2016 Results assessing the neoadjuvant combination immunotherapy with ipilimumab (n=27) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top